China’s pharmaceuticals ambition is getting harder to ignore

China is no longer content to be the world’s manufacturing base for pharmaceuticals. Its latest five-year plan makes the ambition considerably more disruptive. By 2030, the country aims for at least 25% of first-in-class drugs to originate in China, reinforcing the country’s emergence as a global centre of innovative R&D.

The scale of the shift is already visible. By the end of 2025, roughly one-third of the global innovative drug pipeline was in China. The next five years are designed to turn that pipeline into commercial and strategic power.

The Chinese government’s five-year plan for the pharmaceutical industry sets out an explicit objective to achieve a leap in the sector’s competitiveness and international influence between 2026 and 2030. The first-in-class target is among 10 objectives established in the plan and covers both active clinical programs and approved products.

Beijing is backing that ambition with policy support for drugmakers pursuing new targets, mechanisms and modalities. Major infectious and chronic diseases, along with rare and paediatric conditions, are identified as priority areas. The ambitions do not stop at drug discovery. By 2030, the government wants 50 domestic drugmakers to generate at least 10 billion yuan ($1.5 billion) in annual sales. It also wants five Chinese products to become global blockbusters.

The licensing market suggests that international pharma is already treating China’s biotech sector as a serious source of innovation rather than simply a lower-cost development base.

Top Chinese licensing deals by upfront value in 2025-26 include Pfizer licensing from 3Sbio in oncology for $1.35 billion in 2025; AstraZeneca licensing from CSPC Pharmaceutical in endocrine and metabolic disease for $1.2 billion in 2026; and Takeda licensing from Innovent Biologics in oncology for $1.2 billion.

That shift has direct implications for Australian biotech and pharmaceutical companies. As Chinese biotechs become more productive sources of novel assets, they increasingly compete for the same global pools of licensing capital, strategic partnerships and investor attention.

Publication of the five-year plan also coincides with a report that the U.S. is considering largely exempting the pharmaceutical industry from restrictions on deals with Chinese companies. Under rules being drafted by the Treasury Department, U.S. drugmakers will be allowed to invest in Chinese drug candidates, provided the molecules are unrelated to pathogens or biotechnology that could be weaponised.

But the policy debate is far from settled. Some U.S. lawmakers are concerned that capital from U.S. drugmakers could end up accelerating the rise of China’s pharmaceutical sector, precisely the outcome Beijing’s five-year plan is designed to achieve.

For China-focused biotech venture investors, the opportunity is therefore more nuanced than simply identifying promising companies. The central challenge is capturing the value created by those assets at exit.

Western pharmaceutical companies can license Chinese-originated assets with relative ease. Acquiring the underlying companies is considerably more complicated. The distinction is important because the U.S. remains the world’s largest commercial pharmaceutical market, while M&A represents a critical component of venture-capital returns.

Corporate governance can compound that difficulty. In many Chinese biotechs, founders and controlling shareholders retain substantial influence over strategic decisions and, in some cases, can effectively determine whether a company is sold despite the preferences of other shareholders. That structural constraint is one factor contributing to the migration of some historically China-focused LP capital towards U.S.-focused biotech funds.

For U.S.-only biotech investors, China’s rise presents a different challenge.

Chinese-origin assets are increasingly competing for the same pharmaceutical licensing budgets and, in doing so, may capture economic value that might otherwise accrue to U.S.-originated biotech. The pace of change is striking. In the first quarter of 2026, China-origin assets accounted for 50% of large pharmaceutical licensing transactions involving upfront payments above $50 million, and 75% of the associated upfront payment value.

For global asset pickers, however, the same structural shift creates a broader opportunity.

China’s expanding biotech sector is creating a larger pool of potentially attractive assets. Investors willing to source across geographies can access those assets, develop them through other markets and capture financing or M&A value outside China.

China’s five-year plan is therefore about more than producing more drugs. It is an attempt to move the country further up the value chain, from supplying the pharmaceutical industry to shaping what the industry develops, licenses and ultimately commercialises.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.